ArticlePregnancy (Hoboken, N.J.)2026
Streamlining intrapartum glycemic control: Subcutaneous insulin for intrapartum diabetes management.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Optimal strategies for intrapartum glycemic control among patients with gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM) remain uncertain. In 2024, our labor and delivery unit implemented a subcutaneous (SC) insulin protocol to replace routine intravenous (IV) insulin initiation when glucose exceeded a treatment threshold. We hypothesized that this change would not worsen neonatal outcomes and would improve nursing (RN) satisfaction. Methods: We conducted a retrospective cohort quality improvement study of patients with GDM or T2DM who delivered at ≥36 weeks between March 2021 and December 2025. July 2024, when the protocol was introduced, was excluded as a washout period. The intervention included both a shift to SC insulin-first management and standardization of intrapartum glycemic treatment to a target of ≤ 120 mg/dL. The primary outcome was a composite of neonatal hypoglycemia or neonatal intensive care unit (NICU) admission for hypoglycemia within 24 h of life. Secondary outcomes included IV insulin duration and RN satisfaction. Outcomes were compared before and after implementation. Poisson regression with an interrupted time series framework assessed pre-implementation trends, immediate level changes, and post-implementation trends in the primary composite outcome. Multivariable logistic regression evaluated associations between insulin modality and the primary outcome. Surveys were analyzed by Wilcoxon rank-sum tests. Results: Of 1140 deliveries in the analytic cohort, the primary outcome occurred in 269 (23.6%). Rates were similar before and after protocol implementation (23.4% vs. 23.9%, Conclusion: Implementation of an SC insulin-first intrapartum diabetes management protocol for patients with GDM and T2DM was not associated with increased neonatal hypoglycemia nor NICU admission for hypoglycemia. The protocol was associated with improved RN satisfaction. This approach may offer a pragmatic alternative to routine IV insulin initiation during labor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.